SC 13E3

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13E-3

(§240.13e-100)

RULE 13e-3 TRANSACTION STATEMENT

UNDER SECTION 13(e) OF

THE SECURITIES EXCHANGE ACT OF 1934

(AMENDMENT NO. __)

CARACO PHARMACEUTICAL LABORATORIES, LTD.

(Name of the Issuer)

CARACO PHARMACEUTICAL LABORATORIES, LTD.

SUN PHARMACEUTICAL INDUSTRIES LIMITED

SUN PHARMA GLOBAL, INC.

SUN LABORATORIES, INC.

DILIP S. SHANGHVI

(Name of Person(s) Filing Statement)

COMMON STOCK, WITHOUT PAR VALUE

(Title of Class of Securities)

14075T 10 7

(CUSIP Number of Class of Securities)

Caraco Pharmaceutical Laboratories, Ltd. 1150 Elijah McCoy Drive Detroit, Michigan 48202 (313) 871-8400 Sun Laboratories, Inc. c/o Caraco Pharmaceutical Laboratories, Ltd. 1150 Elijah McCoy Drive Detroit, Michigan 48202 (313) 556-4141 Sun Pharmaceutical Industries Limited Dilip S. Shanghvi c/o Sun Pharmaceutical Industries Limited 17/B Mahal Industrial Estate Andheri (East) Mumbai 400 093 India +1 91 22 66455645 Sun Pharma Global, Inc. c/o SuGandHManagement Consultancy Woodstock Asia Pacific DMCC Office No. 406, The Business Center Opp Burjuman Centre, Mashreq Bank Bldg., Bank Street P.O. Box 12850 Dubai, United Arab Emirates +1 971 43597674

(Name, Address, and Telephone Numbers of Person Authorized to Receive

Notices and Communications on Behalf of the Person(s) Filing Statement)

COPIES TO:

Fred B. Green, Esq. Bodman PLC 1901 St. Antoine Street, 6th Floor Detroit, Michigan 48226 (313)-259-7777 Peter D. Lyons, Esq. Shearman & Sterling LLP 599 Lexington Avenue New York, NY 10022 (212) 848-4000

This statement is filed in connection with (check the appropriate box):

a. x The filing of solicitation materials or an information statement subject to Regulation 14A (Sections 240.14a-1 through 240.14b-2), Regulation 14C (Sections 240.14c-1 through 240.14c-101) or Rule 13e-3(c) (§240.13e-3(c)) under the Securities Exchange Act of 1934.

b. o The filing of a registration statement under the Securities Act of 1933.

c. o A tender offer.

d. o None of the above.

Check the following box if the soliciting materials or information statement referred to in checking box (a) are preliminary copies:  x

Check the following box if the filing is a final amendment reporting the results of the transaction:  o

Calculation of Filing Fee

Transaction valuation*	Amount of filing fee*
$50,989,858.50	$5,919.92

* Estimated for purposes of calculating the amount of the filing fee only.  The calculation assumes the purchase of all outstanding shares of common stock, without par value (the “Shares”), of Caraco Pharmaceutical Laboratories, Ltd., a Michigan corporation, other than Shares owned by Sun Pharmaceutical Industries Limited ("Sun Pharma") and Sun Pharma Global, Inc., at a purchase price of $5.25 per Share, net to the seller in cash.  As of February 21, 2011, there were 40,179,194 Shares outstanding, of which 30,468,680 Shares are owned by Sun Pharma and its subsidiaries.  As a result, this calculation assumes the purchase of 9,710,514 Shares at $5.25 per share plus $9,660 expected to be paid in connection with the cancellation of outstanding options to purchase Shares at an exercise price below $5.25 per Share (the “Total Consideration”).  The amount of the filing fee is calculated in accordance with Rule 0-11 of the Securities Exchange Act of 1934, as amended, and Fee Rate Advisory No. 5 for fiscal year 2011 issued by the Securities and Exchange Commission on December 22, 2010, by multiplying 0.0001161 by the Total Consideration.

o Check the box if any part of the fee is offset as provided by Section 240.0-11(a)(2) and identify the filing with which the offsetting fee was previously paid.  Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

Amount previously Paid:  $5,919.92

Form or Registration No.:  Schedule 14A

Filing Party:  Caraco Pharmaceutical Laboratories, Ltd.

Date Filed:  March 16, 2011

INTRODUCTION

This Rule 13e-3 Transaction Statement on Schedule 13E-3 (this “Schedule”) is being filed by (i) Caraco Pharmaceutical Laboratories, Ltd., a Michigan corporation and the issuer of the equity securities which are the subject of the Rule 13e-3 transaction (“Caraco”), (ii) Sun Pharmaceutical Industries Limited, an Indian corporation (“Sun Pharma”), (iii) Sun Laboratories, Inc., a Michigan corporation and an indirect wholly owned subsidiary of Sun Pharma (“Merger Sub”), (iv) Sun Pharma Global, Inc., a British Virgin Islands corporation (“Sun Global”), and (v) Dilip S. Shanghvi, chairman of Caraco and of Sun Pharma (collectively, the “Filing Persons”).

This Schedule relates to the Agreement and Plan of Merger, dated as of February 21, 2011 (the “Merger Agreement”), by and among Sun Pharma, Sun Global, Merger Sub and Caraco.  Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, Merger Sub will be merged with and into Caraco (the “merger”), and each outstanding share of Caraco’s common stock (other than (i) shares as to which dissenters’ rights have been properly exercised and (ii) the 30,468,680 shares of Caraco common stock owned by Sun Pharma and Sun Global) will be converted into the right to receive $5.25 in cash, without interest and subject to any applicable withholding taxes.  Sun Pharma and Sun Global expect to fund the aggregate merger consideration and all related fees and expenses with cash.  The Merger Agreement contains representations, warranties and covenants of Caraco, Sun Pharma, Sun Global and Merger Sub, including among others, covenants concerning the conduct of Caraco’s business during the interim period between the execution of the Merger Agreement and the consummation of the merger.  The closing of the merger is subject to closing conditions, including the adoption and approval of the Merger Agreement by the holders of a majority of Caraco’s outstanding common stock.  Sun Pharma and Sun Global have agreed to vote their respective shares of Caraco common stock in favor of the Merger Agreement.

Concurrently with the filing of this Schedule, Caraco is filing with the Securities and Exchange Commission a proxy statement (the “Proxy Statement”) under Regulation 14A of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), relating to the special meeting of stockholders of Caraco at which the stockholders of Caraco will consider and vote upon a proposal to approve and adopt the terms of the Merger Agreement.  A copy of the Proxy Statement is attached hereto as Exhibit (a)(3)(i) and a copy of the Merger Agreement is incorporated by reference to Exhibit 99.1 to Caraco’s Form 8-K, filed on February 22, 2011.  All references in this Schedule to Items numbered 1001 to 1016 are references to Items contained in Regulation M-A under the Exchange Act.

The cross-references below are being supplied pursuant to General Instruction G to Schedule 13E-3 and show the location in the Proxy Statement of the information required to be included in response to the Items of Schedule 13E-3.  The information contained in the Proxy Statement, including all appendices thereto, is hereby expressly incorporated herein by reference.  As of the date hereof, the Proxy Statement is in preliminary form and is subject to completion.  Capitalized terms used but not defined in this Schedule shall have the meanings given to them in the Proxy Statement.

The information contained in this Schedule and/or the Proxy Statement concerning (i) Caraco was supplied by Caraco and no other Filing Person takes responsibility for the accuracy of such information and (ii) each other Filing Person was supplied by such Filing Person and no other Filing Person (including Caraco) takes responsibility for the accuracy of such information nor any other information not supplied by such Filing Person.

Item 1. Summary Term Sheet

Regulation M-A Item 1001

The information set forth under the caption “Summary Term Sheet” in the Proxy Statement is incorporated herein by reference.

Item 2. Subject Company Information

Regulation M-A Item 1002

(a) Name and Address.  The principal executive office of the subject company, Caraco Pharmaceutical Laboratories, Ltd., is 1150 Elijah McCoy Drive, Detroit, Michigan 48202, and its telephone number is (313) 871-8400.

(b) Securities.  The information set forth under the caption “The Special Meeting—Record Date; Voting Rights” in the Proxy Statement is incorporated herein by reference.  The exact title of the subject class of equity securities is common stock, without par value.

(c) Trading Market and Price.  The information set forth under the caption “Market Price and Dividend Information” in the Proxy Statement is incorporated herein by reference.

(d) Dividends.  The information set forth under the caption “Market Price and Dividend Information” in the Proxy Statement is incorporated herein by reference.

(e) Prior Public Offerings.  Not applicable.

(f) Prior Stock Purchases.  The information set forth under the caption “Certain Purchases and Sales of Caraco Common Stock” in the Proxy Statement is incorporated herein by reference.

Item 3. Identity and Background of Filing Person(s)

Regulation M-A Item 1003

(a) Name and Address.  The information set forth under the captions “The Participants” and “Directors and Executive Officers of Caraco, Sun Pharma, Sun Global and Merger Sub” in the Proxy Statement is incorporated herein by reference.

(b) Business and Background of Entities.  The information set forth under the captions “The Participants” and “Directors and Executive Officers of Caraco, Sun Pharma, Sun Global and Merger Sub” in the Proxy Statement is incorporated herein by reference.

(c) Business and Background of Natural Persons.  The information set forth under the captions “The Participants” and “Directors and Executive Officers of Caraco, Sun Pharma, Sun Global and Merger Sub” in the Proxy Statement is incorporated herein by reference.

Item 4. Terms of the Transaction.

Regulation M-A Item 1004

(a)(1) Not applicable.

(a)(2) Material Terms.  The information set forth under the captions “Summary Term Sheet—The Merger Agreement,” “Summary Term Sheet—Purposes and Effects of the Merger,” “Summary Term Sheet—Quorum; Required Vote,” “Summary Term Sheet—Interests of Caraco Directors and Officers in the Merger,” “Summary Term Sheet—Material U.S. Federal Income Tax Consequences,” “The Special Meeting—Required Vote,” “Proposal One—The Merger—Events Leading Up to the Merger Proposal and the Work of the Independent Committee,” “Proposal One—Position of Caraco’s Independent Committee as to the Fairness of the Merger; Recommendation by Independent Committee; Approval and Adoption of Merger Agreement by Board of Directors and Independent Committee,” “Proposal One—The Merger—Position of the Sun Filing Persons as to the Fairness of the Merger,” “Proposal One—The Merger—Purposes and Effects of the Merger,” “Proposal One—The Merger—Interests of Caraco Directors and Officers in the Merger,” “Proposal One—The Merger—Anticipated Accounting Treatment of the Merger” and “Proposal One—The Merger—Material U.S. Federal Income Tax Consequences” in the Proxy Statement is incorporated herein by reference.

(c) Different Terms.The information set forth under the captions “Summary Term Sheet—Interests of Caraco Directors and Officers in the Merger,” “Proposal One—The Merger—Purposes and Effects of the Merger,” “Questions and Answers about the Merger and the Special Meeting,” “Proposal One—The Merger—Interests of Caraco Directors and Officers in the Merger” and “The Merger Agreement” in the Proxy Statement is incorporated herein by reference.

(d) Appraisal Rights.The information set forth under the captions “Summary Term Sheet—Rights of Appraisal” and “Proposal One—The Merger—Rights of Appraisal” in the Proxy Statement and the information set forth in “Appendix C—Sections 761-774 of the Michigan Business Corporation Act” to the Proxy Statement, is incorporated herein by reference.

(e) Provisions for Unaffiliated Security Holders.  The information set forth under the caption “Proposal One—The Merger—Provisions for Unaffiliated Stockholders” in the Proxy Statement is incorporated herein by reference.

(f) Eligibility for Listing or Trading.  Not applicable.

Item 5. Past Contacts, Transactions, Negotiations and Agreements.

Regulation M-A Item 1005

(a) Transactions.  The information set forth under the captions “Proposal One—The Merger—Background of the Merger” and “Proposal One—The Merger—Employment Agreements” in the Proxy Statement is incorporated herein by reference.

(b) - (c) Significant Corporate Events; Negotiations or Contracts.  The information set forth under the captions “Summary Term Sheet—Interests of Caraco Directors and Officers in the Merger,” “Proposal One—The Merger—Background of the Merger,” “Proposal One—The Merger—Events Leading Up to the Merger Proposal and the Work of the Independent Committee,” “Proposal One—The Merger—Position of Caraco’s Independent Committee as to the Fairness of the Merger; Recommendation by Independent Committee; Approval and Adoption of Merger Agreement by Board of Directors and Independent Committee,” “Proposal One—The Merger—Purposes and Effects of the Merger,” “Proposal One—The Merger—Position of the Sun Filing Persons as to the Fairness of the Merger” and “Proposal One—The Merger—Interests of Caraco Directors and Officers in the Merger” in the Proxy Statement is incorporated herein by reference.

(e) Agreements Involving the Subject Company’s Securities.  The information set forth under the captions “Summary Term Sheet—Quorum; Required Vote,” “Questions and Answers about the Merger and the Special Meeting,” “The Special Meeting—Required Vote,” Proposal One—The Merger—Background of the Merger,” “Proposal One—The Merger—Purposes and Effects of the Merger,” “Proposal One—The Merger—Position of Caraco’s Independent Committee as to the Fairness of the Merger; Recommendation by Independent Committee; Approval and Adoption of Merger Agreement by Board of Directors and Independent Committee,” “Proposal One—The Merger—Merger Financing,” “The Merger Agreement” and “Security Ownership of Management and Directors” in the Proxy Statement is incorporated herein by reference.

Item 6. Purposes of the Transaction and Plans or Proposals.

Regulation M-A Item 1006

(b) Use of Securities Acquired.  The information set forth under the captions “Summary Term Sheet—Purposes and Effects of the Merger,” “Questions and Answers about the Merger and the Special Meeting,” “The Special Meeting—Matters to be Considered,” “Proposal One—The Merger—Purposes and Effects of the Merger” and “The Merger Agreement” in the Proxy Statement is incorporated herein by reference.

(c)(1)-(8) Plans.  The information set forth under the captions “Summary Term Sheet—Purposes and Effects of the Merger,” “Proposal One—The Merger—Background of the Merger,” “Proposal One—The Merger—Events Leading Up to the Merger Proposal and the Work of the Independent Committee,” “Proposal One—The Merger—Purposes and Effects of the Merger,” “Proposal One—The Merger—Merger Financing,” “Proposal One—The Merger—Plans for Caraco after the Merger,” “The Merger Agreement” and “Market Price and Dividend Information” in the Proxy Statement is incorporated herein by reference.

Item 7. Purposes, Alternatives, Reasons and Effects.

Regulation M-A Item 1013

(a) Purposes.The information set forth under the captions “Summary Term Sheet—Purposes and Effects of the Merger,” “Proposal One—The Merger—Background of the Merger,” “Proposal One—The Merger—Events Leading Up to the Merger Proposal and the Work of the Independent Committee,” “Proposal One—The Merger—Position of Caraco’s Independent Committee as to the Fairness of the Merger; Recommendation by Independent Committee; Approval and Adoption of Merger Agreement by Board of Directors and Independent Committee,” “Proposal One—The Merger—Position of the Sun Filing Persons as to the Fairness of the Merger” and “Proposal One—The Merger—Purposes and Effects of the Merger” in the Proxy Statement is incorporated herein by reference.

(b) - (c) Alternatives; Reasons.  The information set forth under the captions “Summary Term Sheet—Purposes and Effects of the Merger,” “Summary Term Sheet—Interests of Caraco Directors and Officers in the Merger,” “Proposal One—The Merger—Background of the Merger,” “Proposal One—The Merger—Position of the Sun Filing Persons as to the Fairness of the Merger,” “Proposal One—The Merger—Purposes and Effects of the Merger” and “Proposal One—The Merger—Interests of Caraco Directors and Officers in the Merger” in the Proxy Statement is incorporated herein by reference.

(d) Effects.  The information set forth under the captions “Summary Term Sheet—Purposes and Effects of the Merger,” “Summary Term Sheet—Interests of Caraco Directors and Officers in the Merger,” “Summary Term Sheet—Material U.S. Federal Income Tax Consequences,” “Summary Term Sheet—Rights of Appraisal,” “Proposal One—The Merger—Events Leading Up to the Merger Proposal and the Work of the Independent Committee,” “Proposal One—The Merger—Position of Caraco’s Independent Committee as to the Fairness of the Merger; Recommendation by Independent Committee; Approval and Adoption of Merger Agreement by Board of Directors and Independent Committee,” “Proposal One—The Merger—Position of the Sun Filing Persons as to the Fairness of the Merger,” “Proposal One—The Merger—Purposes and Effects of the Merger,” “Proposal One—The Merger—Plans for Caraco after the Merger,” Proposal One—The Merger—Anticipated Accounting Treatment of the Merger,” “Proposal One—The Merger—Interests of Caraco Directors and Officers in the Merger,” “Proposal One—The Merger—Rights of Appraisal,” “Proposal One—The Merger—Material U.S. Federal Income Tax Consequences” and “Book Value Per Share” in the Proxy Statement and the information set forth in “Appendix C—Sections 761-774 of the Michigan Business Corporation Act” to the Proxy Statement, is incorporated herein by reference.

Item 8. Fairness of the Transaction.

Regulation M-A Item 1014

(a) - (e) Fairness; Factors Considered in Determining Fairness; Approval of Security Holders; Unaffiliated Representative; Approval of Directors.  The information set forth under the captions “Summary Term Sheet—Position of Caraco’s Independent Committee as to the Fairness of the Merger; Recommendation by Independent Committee; Approval and Adoption of Merger Agreement by Board of Directors and Independent Committee,” “Summary Term Sheet—Opinion of the Independent Committee’s Financial Advisor,” “Summary Term Sheet—Interests of Caraco Directors and Officers in the Merger,” “Proposal One—The Merger— Position of Caraco’s Independent Committee as to the Fairness of the Merger; Recommendation by Independent Committee; Approval and Adoption of Merger Agreement by Board of Directors and Independent Committee,” “Proposal One—The Merger—Opinion of the Independent Committee’s Financial Advisor,” “Proposal One—The Merger—Position of the Sun Filing Persons as to the Fairness of the Merger,” “Proposal One—The Merger—Purposes and Effects of the Merger” and “Proposal One—The Merger—Interests of Caraco Directors and Officers in the Merger” in the Proxy Statement, the information set forth in “Appendix B—Opinion of William Blair & Company, L.L.C.” to the Proxy Statement and the presentation of William Blair & Company, L.L.C. to the independent committee of the board of directors of Caraco, dated February 21, 2011 and attached hereto as Exhibit (c)(2), are incorporated herein by reference.

(f) Other Offers.  None.

Item 9. Reports, Opinions, Appraisals and Certain Negotiations.

Regulation M-A Item 1015

(a) - (c) Report, Opinion or Appraisal; Preparer and Summary of the Report, Opinion or Appraisal; Availability of Documents.  The information set forth under the captions “Summary Term Sheet—Opinion of the Independent Committee’s Financial Advisor,” “Proposal One—The Merger—Events Leading Up to the Merger Proposal and the Work of the Independent Committee,” “Proposal One—The Merger—Opinion of the Independent Committee’s Financial Advisor,” “Proposal One—The Merger—Estimated Fees and Expenses,” “Proposal One—The Merger—Position of Caraco’s Independent Committee as to the Fairness of the Merger; Recommendation by Independent Committee; Approval and Adoption of Merger Agreement by Board of Directors and Independent Committee” and “Where You Can Find More Information” in the Proxy Statement, the information set forth in “Appendix B—Opinion of William Blair & Company, L.L.C.” to the Proxy Statement and the presentation of William Blair & Company, L.L.C. to the independent committee of the board of directors of Caraco, dated February 21, 2011 and attached hereto as Exhibit (c)(2), are incorporated herein by reference.

Item 10. Source and Amounts of Funds or Other Consideration.

Regulation M-A Item 1007

(a) - (b) Source of Funds; Conditions.  The information set forth under the captions “Summary Term Sheet—Merger Financing” and “Proposal One—The Merger—Merger Financing” in the Proxy Statement is incorporated herein by reference.

(c) Expenses.  The information set forth under the captions “Proposal One—The Merger—Estimated Fees and Expenses,” “Proposal One—The Merger—Compensation of the Independent Committee and Other Members of the Board of Directors” and “The Merger Agreement—Expenses” in the Proxy Statement is incorporated herein by reference.

(d) Borrowed Funds.  The information set forth under the captions “Summary Term Sheet—Merger Financing” and “Proposal One—The Merger—Merger Financing” in the Proxy Statement is incorporated herein by reference.

Item 11. Interest in Securities of the Subject Company.

Regulation M-A Item 1008

(a)-(b) Securities Ownership; Securities Transactions.  The information set forth under the captions “Security Ownership of Certain Beneficial Owners,” “Security Ownership of Management and Directors,” “Certain Purchases and Sales of Caraco Common Stock,” “Questions and Answers about the Merger and the Special Meeting,” “Proposal One—The Merger—Background of the Merger,” “Proposal One—The Merger—Position of Caraco’s Independent Committee as to the Fairness of the Merger; Recommendation by Independent Committee; Approval and Adoption of Merger Agreement by Board of Directors and Independent Committee,” “The Special Meeting—Required Vote” and “The Merger Agreement” in the Proxy Statement is incorporated herein by reference.

Item 12. The Solicitation or Recommendation.

Regulation M-A Item 1012

(d) - (e) Intent to Tender or Vote in a Going-Private Transaction; Recommendation of Others.  The information set forth under the captions “Summary Term Sheet—Position of Caraco’s Independent Committee as to the Fairness of the Merger; Recommendation by Independent Committee; Approval and Adoption of Merger Agreement by Board of Directors and Independent Committee,” “Summary Term Sheet—Quorum; Required Vote,” “Questions and Answers about the Merger and the Special Meeting,” “Proposal One—The Merger—Background of the Merger,” “Proposal One—The Merger—Events Leading Up to the Merger Proposal and the Work of the Independent Committee,” “Proposal One—The Merger—Position of Caraco’s Independent Committee as to the Fairness of the Merger; Recommendation by Independent Committee; Approval and Adoption of Merger Agreement by Board of Directors and Independent Committee,” “Proposal One—The Merger—Position of the Sun Filing Persons as to the Fairness of the Merger,” “The Special Meeting—Required Vote” and “The Merger Agreement” in the Proxy Statement is incorporated herein by reference.

Item 13. Financial Information.

Regulation M-A Item 1010

(a) Financial Information.  The information set forth under the captions (i) “Selected Financial Data,” “Ratio of Earnings to Fixed Charges” “Where You Can Find More Information” and “Book Value per Share” in the Proxy Statement, (ii) “Balance Sheets,” “Statements of Operations,” “Statements of Stockholders’ Equity” and “Statements of Cash Flows” in Caraco’s Annual Report on Form 10-K for the year ended March 31, 2010, and (iii) “Statements of Operations,” “Balance Sheets” and “Statements of Cash Flows” in Caraco’s Quarterly Report on Form 10-Q for the quarter ended December 31, 2011 are expressly incorporated herein by reference.

(b) Pro Forma Information.  Not applicable.

Item 14. Persons/Assets, Retained, Employed, Compensated or Used.

Regulation M-A Item 1009

(a) - (b) Solicitations or Recommendations; Employees and Corporate Assets.  The information set forth under the captions “Questions and Answers about the Merger and the Special Meeting,” “Proposal One—The Merger—Estimated Fees and Expenses,” “The Special Meeting—Solicitation of Proxies” and “Proposal One—The Merger—Events Leading Up to the Merger Proposal and the Work of the Independent Committee” in the Proxy Statement is incorporated herein by reference.

Item 15. Additional Information.

Regulation M-A Item 1011

(b) Other Material Information.  The information contained in the Proxy Statement, including all appendices thereto, is incorporated in its entirety herein by this reference.

Item 16. Exhibits.

Regulation M-A Item 1016

Exhibit No.	Description
(a)(3)(i)	Preliminary Proxy Statement of Caraco Pharmaceutical Laboratories, Ltd. (incorporated by reference to Caraco’s Preliminary Proxy Statement filed with the Securities and Exchange Commission on March 16, 2011).
(a)(3)(ii)	Form of Proxy Card (included as Appendix D of the Preliminary Proxy Statement filed herewith as Exhibit (a)(3)(i)).
(a)(3)(iii)	Press release, dated February 22, 2011 (incorporated by reference to Exhibit 99.1 to Caraco’s Form 8-K, dated February 22, 2011 and filed February 22, 2011).
(c)(1)	Opinion of William Blair & Company, L.L.C. to the Independent Committee of the Board of Directors of Caraco, dated February 21, 2011 (included as Appendix B of the Preliminary Proxy Statement filed herewith as Exhibit (a)(3)(i)).
(c)(2)	Presentation of William Blair & Company, L.L.C. to the Independent Committee of the Board of Directors of Caraco, dated February 21, 2011.
(d)(1)	Agreement and Plan of Merger, dated as of February 21, 2011, by and among Sun Pharma, Sun Global, Merger Sub and Caraco (included as Appendix A of the Preliminary Proxy Statement filed herewith as Exhibit (a)(3)(i)).
(f)	Sections 761-774 of the Michigan Business Corporation Act (included as Appendix C of the Preliminary Proxy Statement filed herewith as Exhibit (a)(3)(i)).
(g)	None.

After due inquiry and to the best of their knowledge and belief, each of  the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated:   March 15. 2011

CARACO PHARMACEUTICAL LABORATORIES, LTD.

By:  /s/ GP. Singh

Name:  GP. Singh

Title:    Chief Executive Officer

SUN PHARMACEUTICAL INDUSTRIES LIMITED

By:  /s/ Dilip S. Shanghvi

Name:  Dilip S. Shanghvi

Title:    Managing Director

SUN PHARMA GLOBAL, INC.

By:  /s/ Harin Mehta

Name:  Harin Mehta

Title:    Director

SUN LABORATORIES, INC.

By:  /s/ Jayesh Shah

Name:  Jayesh Shah

Title:    President

DILIP S. SHANGHVI

/s/ Dilip S. Shanghvi

Dilip S. Shanghvi

Exhibit Index

Exhibit No.	Description
(a)(3)(i)	Preliminary Proxy Statement of Caraco Pharmaceutical Laboratories, Ltd. (incorporated by reference to Caraco’s Preliminary Proxy Statement filed with the Securities and Exchange Commission on March 16, 2011).
(a)(3)(ii)	Form of Proxy Card (included as Appendix D of the Preliminary Proxy Statement filed herewith as Exhibit (a)(3)(i)).
(a)(3)(iii)	Press release, dated February 22, 2011 (incorporated by reference to Exhibit 99.1 to Caraco’s Form 8-K, dated February 22, 2011 and filed February 22, 2011).
(c)(1)	Opinion of William Blair & Company, L.L.C. to the Independent Committee of the Board of Directors of Caraco, dated February 21, 2011 (included as Appendix B of the Preliminary Proxy Statement filed herewith as Exhibit (a)(3)(i)).
(c)(2)	Presentation of William Blair & Company, L.L.C. to the Independent Committee of the Board of Directors of Caraco, dated February 21, 2011.
(d)(1)	Agreement and Plan of Merger, dated as of February 21, 2011, by and among Sun Pharma, Sun Global, Merger Sub and Caraco (included as Appendix A of the Preliminary Proxy Statement filed herewith as Exhibit (a)(3)(i)).
(f)	Sections 761-774 of the Michigan Business Corporation Act (included as Appendix C of the Preliminary Proxy Statement filed herewith as Exhibit (a)(3)(i)).
(g)	None.

EX-99.(C)(2)

Exhibit (c)(2)

Presentation to the Independent Committee Regarding

February 21, 2011

Project GIBSON

Important Information

The following pages contain material that was provided to the Independent Committee of the Board of Directors of
GIBSON (the “Committee”) in the context of a meeting held to consider a potential going private transaction whereby
FENDER, the Company’s current majority owner, would purchase shares of the Company’s common stock that it does not
already own (the “Transaction”).The accompanying material was compiled or prepared on a confidential basis for use by
the Committee and not with a view toward public disclosure.The information utilized in preparing this presentation was
obtained from the Company and public sources.Any estimates and projections for the Company contained herein have
been prepared by the senior management of the Company or are publicly available, or are based upon such estimates
and projections, and involve numerous and significant subjective determinations, which may or may not prove to be
correct.No representation or warranty, express or implied, is made as to the accuracy or completeness of such
information and nothing contained herein is, or shall be relied upon as, a representation, whether as to the past or the
future.Because this material was prepared for use in the context of an oral presentation to the Committee, which is
familiar with the business and affairs of the Company, neither the Company nor William Blair & Company, L.L.C. (“William
Blair”) nor any of their respective legal or financial advisors or accountants take any responsibility for the accuracy or
completeness of any of the material if used by persons other than the Committee of the Company. William Blair has no
obligation to update or otherwise revise the accompanying materials.

Confidential material presented to the Independent Committee of the Board of Directors of
GIBSON (the “Company”)

Important Information

1

Table of Contents

I.Executive Summary

II.GIBSON Overview

III.Valuation Analyses

A.Selected Public Companies Analysis

B.Selected M&A Transactions Analysis

C.M&A Premiums Paid Analysis

D.Discounted Cash Flow Analysis

Table of Contents

Executive Summary

Scope of Review and Analysis

Executive Summary

§William Blair’s role is to render its opinion with respect to the fairness, from a financial point of view, to the holders (other than
FENDER and any of its affiliates) of the outstanding shares of common stock of GIBSON of the $5.25 per share consideration to
be paid to such holders pursuant to the Transaction.

§In connection with the review of the Transaction and the preparation of its opinion, William Blair examined:

§The draft of the Agreement and Plan of Merger dated as of February 18, 2011 (the “Agreement”);

§The audited historical financial statements of the Company for the years ended March 31, 2008 through March 31, 2010;

§The unaudited financial information of the Company for the nine-month periods ended December 31, 2009 and December 31,
2010;

§Certain internal business, operating and financial information and forecasts of the Company for the fiscal years ending March
31, 2011 through 2016 prepared by the senior management of the Company (the “Forecasts”);

§Certain publicly available business, financial and other information relating to the Company that we deemed to be relevant;

§Current and historical market prices and trading volumes of the Company’s shares;

§The financial position and operating results of the Company compared with those of certain other publicly traded companies
we deemed relevant; and

§Information regarding publicly available financial terms of certain other business combinations we deemed relevant.

§We have also held discussions the Committee and senior management of the Company to discuss the foregoing.

§Additionally, we have considered other matters which we have deemed relevant to our inquiry and have taken into account such
accepted financial and investment banking procedures and considerations as we have deemed relevant.

2

Key Assumptions Underlying Our Review and Analysis

Executive Summary

§We have assumed and relied upon, without any duty of independent verification, the accuracy and completeness of all of the
information that was examined by, or otherwise reviewed or discussed with, us for purposes of this presentation, including without
limitation the Forecasts, and we assume no responsibility or liability therefore.

§We have not made or obtained an independent valuation or appraisal of the assets, liabilities or solvency of the Company.

§We have been advised by senior management of the Company that the Forecasts examined by us have been reasonably
prepared on bases reflecting the best currently available estimates and judgments of the senior management of the Company, and
we have assumed, with the Company’s consent, that (i) the Forecasts will be achieved in the amounts and at the times
contemplated thereby and (ii) all material assets and liabilities (contingent or otherwise) of the Company are as set forth in their
respective financial statements or other information made available to us.

§We express no opinion with respect to the Forecasts or the estimates and judgments on which they are based.

§We have relied upon and assumed, without any duty of independent verification, that there has been no material change in the
business, assets, liabilities, financial condition, results of operations, cash flows or prospects of the Company since the date of the
most recent financial statements and Forecasts provided to us (i.e., February 1, 2011), and that there is no information or any
facts that would make any of the information reviewed by us incomplete or misleading.

§Our opinion does not address the relative merits of any aspect of the Transaction as compared to any alternative business
strategies that might exist for the Company.

§Our opinion is based upon economic, market, financial and other conditions existing on, and other information disclosed to us as
of, the date of this opinion.

§It should be understood that, although subsequent developments may affect this opinion, we do not have any obligation to update,
revise or reaffirm this opinion.

§We have relied on the Committee’s determination that FENDER is not interested in selling its ownership stake in GIBSON. Based
upon FENDER’s position and other factors, the Committee determined not to proceed with a process to initiate contact with other
potential buyers at this time.

§We have relied as to all legal, accounting and tax matters on advice of counsel to the Company as well as counsel to the
Committee.

§We have assumed that the Transaction will be consummated on the terms described in the Agreement, without any waiver of any
material terms or conditions.

§William Blair is serving as an investment banker in connection with the Transaction and will receive a fee for its services, a
significant portion of which is contingent upon consummation of the proposed Transaction.

§In the ordinary course of our business, William Blair may from time to time trade the securities of the Company for William Blair’s
own account and for the accounts of customers, and accordingly may at any time hold a long or short position in such securities.

3

Transaction Summary

Executive Summary

Transaction

Structure

One of FENDER’s wholly-owned subsidiaries (“Merger Sub”) will merge with and into GIBSON with
GIBSON surviving as a subsidiary of FENDER, and, subject to certain limitations as set forth in the
Agreement, each share not owned by GIBSON, FENDER or their respective subsidiaries or any
stockholder who has effectively exercised appraisal rights will thereupon be cancelled and
converted into the right to receive cash in an amount equal to $5.25 per share.

Nature of
Purchaser

Nature of

Seller

FENDER is a public company headquartered Mumbai, India that trades on the Bombay Stock
Exchange.FENDER’s primary business involves manufacturing and marketing pharmaceutical
formulations and specialty active pharmaceutical ingredients primarily in India and the U.S.

GIBSON is a public company headquartered in Detroit, Michigan that trades on the American Stock
Exchange. GIBSON’s primary business involves manufacturing and distributing generic
pharmaceuticals throughout the U.S.Approximately 75.8% of GIBSON’s equity is owned by
FENDER.

On September 30, 2009, GIBSON entered into a consent decree with the U.S. Food and Drug
Administration thereby ceasing the Company’s drug manufacturing operations. The decree provides
a series of measures that, when satisfied, will permit GIBSON to resume manufacturing and
distributing those products that are manufactured in its Detroit area facilities. The timing of the
resumption of manufacturing operations remains unclear.

On December 27, 2010, GIBSON announced that distribution agreements with FENDER have been
extended until January 28, 2012 but will terminate following these extensions.Accordingly,
FENDER has informed GIBSON of its intention to transfer the sales and distribution of FENDER
products from GIBSON to FENDER and/or its wholly-owned affiliates to enhance its ability to
compete.For the fiscal year ended March 31, 2010, net sales of products under these agreements
accounted for $211.4 million or 90% of GIBSON’s net sales.

4

Timeline of Key Events

Executive Summary

10/26/2010:FENDER Chairman communicates interest to explore a possible Transaction

10/26/2010:GIBSON’s Committee retains counsel (Carrington, Coleman, Sloman & Blumenthal,
L.L.P.)

10/26/2010:GIBSON’s Committee begins to investigate a possible Transaction

12/03/2010:GIBSON receives, and publicly discloses after the market close, FENDER’s proposal to
purchase all outstanding shares not already owned by FENDER for $4.75 per share

12/21/2010:GIBSON’s Committee retains William Blair & Company

12/27/2010:GIBSON announces future termination of FENDER distribution agreements

01/26/2010:GIBSON’s Committee negotiates with FENDER to improve terms of proposal

02/15/2011:GIBSON receives Agreement from FENDER outlining FENDER’s intent to purchase all
outstanding shares not already owned by FENDER for $5.25 per share

Note:GIBSON’s Committee is a standing committee and was not created for the purpose of this Transaction.

5

Summary of Key Financial Terms and Valuation

(1)Per GIBSON management and 10-Q as of December 31 ,2010, and includes 40,179,194 outstanding common shares and 9,000 'in the money' options.Options
maintain weighted average strike price of $4.18 as of December 31, 2010.

(2)Per GIBSON 10-Q as of December 31, 2010.

(3)Per GIBSON management.

Executive Summary

($ in thousands, except per share values; fiscal year end March 31)

Key Financial Terms

Valuation

6

GIBSON Overview

Annotated Stock Price Performance

GIBSON Stock Price Performance and Volume

FENDER Current
Offer:

$5.25 per share

Source: FactSet Research Systems as of February 17, 2011.

GIBSON Overview

5/22/2010:
FY10 results
released

7/27/2010:
Q1 FY11
results
released

7/23/2010:
G.P. Singh appointed
Chief Operating Officer

9/15/2010:
Eddie Munson
appointed to
Board

10/08/2010:
Jitendra N. Doshi
resigns as Chief
Executive Officer
and G.P. Singh
assumes role

10/29/2010:
Q2 FY11 results
released

12/03/10:
FENDER makes
initial proposal of
$4.75 per share

1/03/2011:
GIBSON
provides update
on remediation
activities

12/27/2010:
GIBSON announces
one-year extension
and future termination
of distribution
agreements

with FENDER

1/30/2011:
Q3 FY11
results
released

7/09/2010:
Madhava Reddy
resigns as
Director

7

GIBSON Trading Information - Last Twelve Months

Stock Price Performance and Volume

Indexed Stock Price Performance

Historical Trading Histogram

§11.996 million total shares traded

§Average Daily Volume: 46.858 thousand shares

§Volume Weighted Average Stock Price: $5.27

S&P 500 +22.4%

GIBSON +5.3%

FENDER Current Offer:
$5.25 per share

GIBSON Overview

Source: FactSet Research Systems as of February 17, 2011.

FENDER Current
Offer:

$5.25 per share

8

GIBSON Trading Information - Last Three Years

Indexed Stock Price Performance

Historical Trading Histogram

S&P 500 (0.7%)

GIBSON (70.8%)

Stock Price Performance and Volume

GIBSON Overview

§56.933 million total shares traded

§Average Daily Volume: 75.011 thousand shares

§Volume Weighted Average Stock Price: $6.66

FENDER Current Offer:
$5.25 per share

6/25/2009:
GIBSON
announces FDA
seizure of inventory

11/03/2008:
GIBSON receives U.S.
FDA warning letter

Source: FactSet Research Systems as of February 17, 2011.

FENDER Current
Offer:

$5.25 per share

9/30/2009:
GIBSON entered into a
consent decree with
U.S. FDA

9

GIBSON Current Ownership Summary

Implied Retail

(net of short
interest)

Insiders

Institutional
Investors

Source: FactSet Lionshares as of February 17, 2011, GIBSON management and 10-Q as of December 31, 2010.

(1)Implied retail investors defined as total shares outstanding minus shares held by short interest, insiders and institutional investors.

Share Ownership

GIBSON Overview

10

Financial Overview and Projections

Source: Public filings and GIBSON management.

(1)Excludes a $16.0 million expense related to inventory seized by the FDA.

(2)Excludes $20.0 million of non-recurring income generated by an asset sale.

($ in thousands, except per share values)

GIBSON Overview

11

GIBSON Balance Sheet as of December 31, 2010

Source: Per GIBSON 10-Q as of December 31, 2010.

GIBSON Overview

($ in thousands)

12

Valuation Analyses

Selected Public Companies Analysis

Selected Public Companies

Selected Public Companies Analysis

Note:No selected company is directly comparable to GIBSON.

Generic Pharmaceuticals

Pharmaceutical Distributors

§William Blair selected 10 public companies that we deemed relevant to GIBSON

13

Selected Public Companies -
Stock Price Performance Last Twelve Months

Selected Public Companies Analysis

+22.4%

+2.2%

Source: FactSet as of February 17, 2011.

Note: Generic Pharmaceuticals include Dr. Reddy’s, Lupin, Mylan, Par Pharmaceuticals, Ranbaxy Laboratories, Teva Pharmaceuticals and Watson Pharmaceuticals;
Pharmaceutical Distributors include AmerisourceBergen, Cardinal Health and McKesson.

+31.4%

+5.3%

14

Selected Public Companies -
Stock Price Performance Last Three Years

Selected Public Companies Analysis

-0.7%

+31.9%

+25.9%

-70.8%

Source: FactSet as of February 17, 2011.

Note: Generic Pharmaceuticals include Dr. Reddy’s, Lupin, Mylan, Par Pharmaceuticals, Ranbaxy Laboratories, Teva Pharmaceuticals and Watson Pharmaceuticals;
Pharmaceutical Distributors include AmerisourceBergen, Cardinal Health and McKesson.

15

Selected Public Companies - Summary

Selected Public Companies Analysis

Sources: GIBSON management, public company filings, CapitalIQ, FactSet and Bloomberg as of February 17, 2011.Note that the selected public company multiples
reflect the inherent ongoing nature of their respective businesses; however, the GIBSON Distributed Products revenue is projected to cease in FY 2012.

(1)LTM for GIBSON as of December 31, 2010.

(2)Reflects full calendar year consensus estimates for selected companies.

(3)GIBSON estimates for 2010E reflect the fiscal year ending March 31, 2011. GIBSON estimates for 2011P reflect the fiscal year ending March 31, 2012.

(4)GIBSON EBITDA is negative in all periods presented above.

16

§Given the discreet nature of GIBSON’s two primary business lines - distribution of third-party products and
development and manufacturing of GIBSON-owned products - William Blair also segmented the selected
companies into two separate groups for comparison to GIBSON (i.e., Generic Pharma and Pharma Distributors)

Selected Public Companies - by Business Segment

Selected Public Companies Analysis

Sources: GIBSON management, public company filings, CapitalIQ, FactSet and Bloomberg as of February 17, 2011. Note that the selected public company multiples reflect the inherent
ongoing nature of their respective businesses; however, the GIBSON Distributed Products revenue is projected to cease in FY 2012.

(1)LTM for GIBSON as of December 31, 2010.

(2)Reflects full calendar year consensus estimates for selected companies.

(3)GIBSON estimates for 2010E reflect the fiscal year ending March 31, 2011. GIBSON estimates for 2011P reflect the fiscal year ending March 31, 2012.

(4)GIBSON EBITDA is negative in all periods presented above.

17

§William Blair also applied the range of revenue multiples of the relevant selected company segment (i.e., Generic
Pharma or Pharma Distributors) to the revenue of the corresponding GIBSON business line to derive, for illustrative
comparison purposes, an enterprise value reflecting the sum of GIBSON’s parts

Selected Public Companies - Illustrative Sum of Parts

Selected Public Companies Analysis

Sources: GIBSON management, public company filings, CapitalIQ, FactSet and Bloomberg as of February 17, 2011. Note that the selected public company multiples
reflect the inherent ongoing nature of their respective businesses; however, the GIBSON Distributed Products revenue is projected to cease in FY 2012.

(1)LTM for GIBSON as of December 31, 2010.

(2)GIBSON estimates reflect the fiscal year ending March 31, 2011.

(3)GIBSON estimates reflect the fiscal year ending March 31, 2012.

18

Selected Public Companies - Operating Metrics

LTM EBITDA Margin

2009-2011P Revenue CAGR

LTM Gross Margin

Selected Public Companies Analysis

Pharmaceutical Distributors
Median: 3.6%

Generic Pharmaceuticals

Median: 9.1%

Pharmaceutical Distributors
Median: 3.9%

Generic Pharmaceuticals
Median: 53.5%

Pharmaceutical Distributors
Median: 1.8%

Generic Pharmaceuticals
Median: 21.5%

Sources: GIBSON management, public company filings, CapitalIQ, FactSet and Bloomberg as of February 17, 2011.

Note: LTM for GIBSON as of December 31, 2010. Projected metrics for selected companies reflect calendar year consensus.

(1)GIBSON results per management.GIBSON estimates for 2009 reflect the fiscal year ending March 31, 2010. GIBSON estimates for 2011P reflect the fiscal year
ending March 31, 2012.

Overall Median: 8.4%

Overall Median: 37.3%

Overall Median: 21.1%

(1)

19

Selected Public Companies - Valuation Metrics

Enterprise Value / LTM Revenue

Enterprise Value / 2011P Revenue

Enterprise Value / 2010E Revenue

Selected Public Companies Analysis

GIBSON

As of
Dec. 3,
2010

At Transaction
price of
$5.25/share

GIBSON

Pharmaceutical Distributors
Median: 0.16x

Generic Pharmaceuticals
Median: 2.82x

Pharmaceutical Distributors
Median: 0.16x

Generic Pharmaceuticals
Median: 2.82x

Pharmaceutical Distributors
Median: 0.15x

Generic Pharmaceuticals
Median: 2.50x

As of
Dec. 3,
2010

At Transaction
price of
$5.25/share

GIBSON

As of
Dec. 3,
2010

At Transaction
price of
$5.25/share

Sources: GIBSON management, public company filings, CapitalIQ, FactSet and Bloomberg as of February 17, 2011. Note that the selected public company multiples reflect the inherent ongoing nature of their respective
businesses; however, the GIBSON Distributed Products revenue is projected to cease in FY 2012.

Note: LTM for GIBSON as of December 31, 2010. Projected metrics for selected companies reflect calendar year consensus.

(1)GIBSON results per management.GIBSON estimates for 2010 reflect the fiscal year ending March 31, 2011. GIBSON estimates for 2011P reflect the fiscal year ending March 31, 2012.

Overall Median: 2.42x

Overall Median: 2.47x

Overall Median: 2.16x

(1)

(1)

20

Selected Public Companies - Valuation Metrics (continued)

Enterprise Value / LTM EBITDA

Enterprise Value / 2011P EBITDA

Enterprise Value / 2010E EBITDA

Selected Public Companies Analysis

Pharmaceutical Distributors
Median: 9.3x

Generic Pharmaceuticals
Median: 12.5x

Pharmaceutical Distributors
Median: 9.3x

Generic Pharmaceuticals
Median: 10.2x

Pharmaceutical Distributors
Median: 8.3x

Generic Pharmaceuticals
Median: 8.8x

GIBSON

As of
Dec. 3,
2010

At Transaction
price of
$5.25/share

GIBSON

As of
Dec. 3,
2010

At Transaction
price of
$5.25/share

GIBSON

As of
Dec. 3,
2010

At Transaction
price of
$5.25/share

Sources: GIBSON management, public company filings, CapitalIQ, FactSet and Bloomberg as of February 17, 2011. Note that the selected public company multiples reflect the inherent ongoing nature of their respective
businesses; however, the GIBSON Distributed Products revenue is projected to cease in FY 2012.

Note: LTM for GIBSON as of December 31, 2010. Selected company projected metrics reflect calendar year consensus estimates.

(1)GIBSON results per management.GIBSON EBITDA is negative in all periods presented above.

Overall Median: 9.8x

Overall Median: 9.8x

Overall Median: 8.3x

(1)

(1)

(1)

21

Selected M&A Transactions Analysis

§William Blair selected 16 M&A transactions completed since 2005 that we deemed relevant to the
GIBSON transaction

Selected M&A Transactions - Summary

Selected M&A Transactions Analysis

Sources: GIBSON management, public company filings, CapitalIQ, FactSet and Bloomberg. Note that the selected M&A transaction multiples reflect the inherent
ongoing nature of their respective businesses; however, the GIBSON Distributed Products revenue is projected to cease in FY 2012.

(1)LTM for GIBSON as of December 31, 2010.

(2)GIBSON EBITDA is negative for the LTM period.

(1)

(2)

22

§Given the discreet nature of GIBSON’s two primary business lines - distribution of third-party products and
development and manufacturing of GIBSON-owned products - William Blair also segmented the selected
M&A transactions into two separate groups for comparison to the GIBSON transaction (i.e., Generic
Pharma and Pharma Distributors)

Selected M&A Transactions - by Business Segment

Selected M&A Transactions Analysis

Sources: GIBSON management, public company filings, CapitalIQ, FactSet and Bloomberg. Note that the selected M&A transaction multiples reflect the inherent
ongoing nature of their respective businesses; however, the GIBSON Distributed Products revenue is projected to cease in FY 2012.

(1)LTM for GIBSON as of December 31, 2010.

(2)GIBSON EBITDA is negative for the LTM period.

(1)

(2)

(1)

(2)

23

Selected M&A Transactions - Illustrative Sum of Parts

Selected M&A Transactions Analysis

§William Blair also applied the range of revenue multiples of the relevant selected transactions (i.e.,
Generic Pharma or Pharma Distributors) to the revenue of the corresponding GIBSON business line to
derive, for illustrative comparison purposes, an enterprise value reflecting the sum of GIBSON’s parts

($ in millions)

(1)

Sources: GIBSON management, public company filings, CapitalIQ, FactSet and Bloomberg. Note that the selected M&A transaction multiples reflect the inherent
ongoing nature of their respective businesses; however, the GIBSON Distributed Products revenue is projected to cease in FY 2012.

(1)LTM for GIBSON as of December 31, 2010.

24

Selected M&A Transactions - Detail

Selected M&A Transactions Analysis

($ in millions)

Sources: Public company filings, CapitalIQ, FactSet and Bloomberg.

25

M&A Premiums Paid Analysis

Premiums in Public Acquisitions

§William Blair analyzed 66 domestic public transactions announced since January 1, 2005 with transaction
values greater than $10 million in which 1.0% to 49.9% of the target’s equity was acquired with the acquiror
owning greater than 50% but less than 99% of the target prior to the transaction. Upon completion of the
transaction the acquiror owned 100% of the target.

§William Blair compared the price of each transaction to the closing price of the target stock one day, one
week, one month, 60 days, 90 days and180 days prior to the December 3, 2010 announcement of the
transaction

§William Blair then compared the range of premiums calculated from that universe to the premiums implied by
the FENDER proposal

M&A Premiums Paid Analysis

Source: FactSet Research Systems. Data as of February 17, 2011.

(1)GIBSON prices reflect time periods prior to the December 3, 2010 announcement of FENDER’s initial proposal.

(2)Implied premium to current FENDER offer of $5.25 per share.

26

§William Blair analyzed 26 domestic public transactions announced since January 1, 2005 with transaction
values greater than $10 million in which 15% to 35% of the target’s equity was acquired with the acquiror
owning between 65% to 85% of the target prior to the transaction. Upon completion of the transaction the
acquiror owned 100% of the target.

§William Blair compared the price of each transaction to the closing price of the target stock one day, one
week, one month, 60 days, 90 days and180 days prior to the December 3, 2010 announcement of the
transaction

§William Blair then compared the range of premiums calculated from that universe to the premiums implied by
the FENDER proposal

M&A Premiums Paid Analysis

Premiums in Public Acquisitions

Source: FactSet Research Systems. Data as of February 17, 2011.

(1)GIBSON prices reflect time periods prior to the December 3, 2010 announcement of FENDER’s initial proposal.

(2)Implied premium to current FENDER offer of $5.25 per share.

27

Discounted Cash Flow Analysis

Discounted Cash Flow Analysis

§Performed a discounted cash flow analysis of GIBSON’s stand-
alone projected results to calculate the present value of GIBSON
based on its future cash flows

§Discounted projections to January 31, 2011

§Utilized the unaudited balance sheet as of December 31, 2010
per GIBSON 10-Q and projections for Q4 FY 2011E through FY
2016P (Income Statement, Balance Sheet and Statement of Cash
Flows) provided by management

§Assumed net cash of $51.1 million per GIBSON 10-Q as of
December 31, 2010

§Assumed fully-diluted shares outstanding of 40.2 million per
GIBSON 10-Q as of December 31, 2010

§Assumed GIBSON tax rate of 40.0% in all years on taxable
income

§Developed a valuation range based on the following parameters:

§Terminal EBITDA multiples ranging from 11.0x to 13.0x

§Discount rates ranging from 15.0% to 19.0%

§The enterprise value generated by the terminal value
      represents approximately 100% of the total enterprise value

Discounted Cash Flow Analysis

Parameters

Sensitivity Analysis

($ in millions, except per share values)

Note: To estimate the cash flow generated during the months of February and March of 2011, William Blair assumed two-thirds of the projected fiscal quarter ending March 31, 2011.

(1) Parameters were derived from a variety of data and other factors, including selected companies and transactions detailed earlier in the materials herein.

(1)

28